Affimed (AFMD) Scheduled to Post Quarterly Earnings on Thursday

Affimed (NASDAQ:AFMD) will be issuing its quarterly earnings data before the market opens on Thursday, November 14th. Analysts expect the company to announce earnings of ($1.14) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Affimed (NASDAQ:AFMD) last issued its quarterly earnings data on Thursday, September 5th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.09). Affimed had a negative net margin of 2,922.74% and a negative return on equity of 155.30%. The company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $1.67 million. On average, analysts expect Affimed to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Affimed Trading Down 1.6 %

NASDAQ:AFMD opened at $3.76 on Wednesday. The company has a quick ratio of 2.71, a current ratio of 2.71 and a debt-to-equity ratio of 0.13. The company has a 50 day simple moving average of $3.50 and a two-hundred day simple moving average of $4.55. Affimed has a 12 month low of $2.92 and a 12 month high of $8.95.

Wall Street Analyst Weigh In

A number of research firms recently commented on AFMD. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Affimed in a research report on Friday, September 6th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Affimed in a research note on Monday, September 9th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.00.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.